Global Health
Global Health
Healthcare ServicesKey Fundamentals
SmallcapHospitalsHealthcare ServicesTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has delivered good profit growth of 80.7% CAGR over last 5 years
Weaknesses
1- Stock is trading at 9.21 times its book value
Growth Rate
AI Analysis — Bull vs Bear
Global Health Ltd (Medanta) has a market capitalisation of about ₹39,930 Cr and trades at a P/E of 73.3x and a P/B of 10.22x. Sales have grown at an 18% CAGR over 3 years and 21% on a TTM basis, with ROE steady at 15-16%. TTM profit growth is flat at 0%, which contrasts with the 81% 5-year profit CAGR, a figure that starts from a low base.
- Profit has compounded at 80.7% CAGR over 5 years and 19% over 3 years, showing that earnings have scaled strongly as the hospital network matured.
- Revenue growth is strong and consistent: 21% TTM, 18% 3-year CAGR and 25% 5-year CAGR, which points to sustained demand and capacity ramp-up.
- ROE has held in a narrow 15-16% band (15% last year, 16% over 3 and 5 years), which shows stable capital efficiency during an expansion phase.
- Sales growth has sped up from a 12% 10-year CAGR to a 25% 5-year CAGR, suggesting the business has moved into a higher-growth phase.
- The stock has returned a 29% CAGR over 3 years and 15% over 1 year, reflecting sustained market recognition of its growth.
- At about ₹39,930 Cr market cap, the company is one of the larger listed hospital operators in India, which gives it scale in a sector with structural demand tailwinds.
- Profit growth of 13% CAGR over 10 years shows a long record of profitable growth, not just a recent upswing.
- The P/E of 73.3x implies an earnings yield of only about 1.4%, so the valuation already assumes strong future growth and leaves little room for missed expectations.
- P/B of 10.22x means the stock trades at more than 10 times book value (implied book value of about ₹3,900 Cr against a ₹39,930 Cr market cap).
- TTM profit growth is 0% while TTM sales grew 21%, which points to margin compression, possibly from new-hospital ramp-up costs, depreciation or higher operating expenses.
- The 80.7% 5-year profit CAGR is flattered by a low starting base; the 3-year profit CAGR of 19% is more representative and is modest against a 73.3x P/E.
- ROE of 15% last year is below the 16% 3- and 5-year averages. At 10.22x book, a 15% ROE is modest relative to the premium investors are paying.
- Dividend yield of 0.03% gives almost no income cushion, so returns depend almost entirely on price appreciation.
- Stock returns slowed from a 29% 3-year CAGR to 15% over the last year, in line with the flattening in profit growth.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Sizeable upfront land capex Sep 29
Global Health committed about ₹165.82 crore for a freehold land parcel in Ghaziabad. Building the hospital will need further heavy capex before it earns any revenue.
- Project approvals still pending Sep 28
The proposed 350+ bed hospital still needs customary and statutory approvals plus Board approval, and the detailed project plan is still being prepared. Timelines and total project cost have not been disclosed.
- Ghaziabad land for 350+ beds Sep 29
Global Health won 10,560.36 sq. metres at Siddharth Vihar, Ghaziabad, for ₹165.82 crore in a UPAVP online auction. The site can hold a 350+ bed tertiary/quaternary hospital serving Ghaziabad, Meerut, Hapur, Bulandshahr and eastern Delhi.
- Strengthening Delhi-NCR network Sep 29
The Ghaziabad project would complement Medanta's operating Noida hospital and deepen its presence in eastern and central NCR. CEO Pankaj Sahni called Ghaziabad a compelling long-term opportunity because demand for specialised care is rising.
- Robust expansion pipeline Sep 29
As of 30 June 2026, Medanta runs 6 hospitals with 3,737 installed beds and over 2,400 doctors. It also has 5 upcoming hospitals in Mumbai, Delhi (Pitampura, South Delhi), Guwahati and Varanasi, and Ghaziabad adds to that pipeline.
- Active institutional investor outreach Sep 22
Management held a series of one-to-one meetings in September 2026: Polar Capital (Sep 10), Chikara and a Jefferies-hosted Lucknow meet (Sep 14), analyst sessions (Sep 17-18), USS Investment Management (Sep 23) and Arohi Asset Management (Sep 25). The company said no unpublished price-sensitive information would be shared.
- ₹0.50 final dividend at AGM Sep 16
At its 22nd AGM on September 16, 2026, Global Health declared a final FY26 dividend of ₹0.50 per share. Pankaj Sahni was re-elected as director.
TL;DR: Global Health is expanding steadily. The ₹165.82 crore Ghaziabad land buy for a planned 350+ bed hospital strengthens its Delhi-NCR footprint, alongside 5 other hospitals in the pipeline on top of its 3,737-bed base. The main risks are execution: board and statutory approvals are pending, and further construction capex is undisclosed, so returns are years away. The token ₹0.50 dividend shows the company is putting cash back into growth, and heavy institutional engagement suggests strong investor interest. Overall the trend is improving, and the next things to watch are Board approval, the capex size and the timeline for the Ghaziabad project.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 780 | 844 | 836 | 809 | 861 | 957 | 943 | 931 | 1,031 | 1,099 | 1,121 | 1,159 | 1,304 |
| Expenses | 595 | 631 | 620 | 629 | 675 | 728 | 706 | 707 | 784 | 868 | 904 | 915 | 1,017 |
| Operating Profit | 184 | 213 | 216 | 179 | 186 | 228 | 238 | 225 | 247 | 231 | 217 | 244 | 287 |
| OPM % | 24% | 25% | 26% | 22% | 22% | 24% | 25% | 24% | 24% | 21% | 19% | 21% | 22% |
| Other Income | 15 | 21 | 18 | 27 | 22 | 18 | 16 | -27 | 20 | 36 | -15 | 37 | 22 |
| Interest | 18 | 20 | 18 | 18 | 18 | 16 | 16 | 15 | 14 | 17 | 22 | 27 | 27 |
| Depreciation | 40 | 43 | 44 | 45 | 47 | 49 | 48 | 49 | 45 | 50 | 61 | 67 | 69 |
| PBT | 141 | 171 | 172 | 143 | 144 | 181 | 189 | 133 | 208 | 200 | 120 | 187 | 213 |
| Tax % | 28% | 27% | 28% | 11% | 26% | 28% | 24% | 24% | 24% | 21% | 21% | 24% | 26% |
| Net Profit | 102 | 125 | 124 | 127 | 106 | 131 | 143 | 101 | 159 | 158 | 95 | 142 | 157 |
| EPS in Rs | 3.8 | 4.66 | 4.61 | 4.74 | 3.96 | 4.87 | 5.32 | 3.78 | 5.92 | 5.89 | 3.54 | 5.36 | 5.9 |
Profit & Loss
| Particulars | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,382 | 1,343 | 1,456 | 1,500 | 1,447 | 2,167 | 2,710 | 3,275 | 3,692 | 4,410 | 4,683 |
| Expenses | 1,081 | 1,218 | 1,283 | 1,309 | 1,250 | 1,709 | 2,073 | 2,466 | 2,806 | 3,480 | 3,705 |
| Operating Profit | 301 | 125 | 172 | 192 | 197 | 458 | 637 | 809 | 886 | 930 | 979 |
| OPM % | 22% | 9% | 12% | 13% | 14% | 21% | 24% | 25% | 24% | 21% | 21% |
| Other Income | 45 | 49 | 50 | 44 | 31 | 39 | 49 | 75 | 29 | 98 | 80 |
| Interest | 14 | 28 | 38 | 57 | 73 | 86 | 86 | 84 | 74 | 90 | 92 |
| Depreciation | 70 | 86 | 102 | 115 | 123 | 130 | 150 | 173 | 194 | 223 | 246 |
| PBT | 262 | 60 | 83 | 64 | 32 | 281 | 449 | 627 | 647 | 715 | 720 |
| Tax % | 35% | 45% | 38% | 43% | 11% | 30% | 27% | 24% | 26% | 23% | — |
| Net Profit | 170 | 33 | 51 | 36 | 29 | 196 | 326 | 478 | 481 | 554 | 552 |
| EPS in Rs | 35.1 | 6.78 | 10.44 | 7.36 | 5.81 | 7.75 | 12.16 | 17.81 | 17.92 | 20.7 | 20.69 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2% | — |
Balance Sheet
| Particulars | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 48 | 48 | 49 | 49 | 50 | 51 | 54 | 54 | 54 | 54 |
| Reserves | 976 | 1,136 | 1,246 | 1,300 | 1,333 | 1,565 | 2,375 | 2,852 | 3,333 | 3,908 |
| Borrowings | 165 | 456 | 787 | 929 | 931 | 1,109 | 1,122 | 802 | 718 | 1,190 |
| Other Liabilities | 295 | 343 | 347 | 388 | 380 | 421 | 547 | 572 | 662 | 753 |
| Total Liabilities | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 |
| Fixed Assets | 914 | 1,094 | 1,194 | 1,703 | 1,616 | 1,776 | 2,050 | 2,236 | 2,514 | 3,795 |
| CWIP | 12 | 317 | 666 | 382 | 464 | 439 | 327 | 388 | 533 | 132 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Other Assets | 559 | 573 | 570 | 581 | 615 | 930 | 1,720 | 1,656 | 1,716 | 1,975 |
| Total Assets | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 |
Cash Flow
| Particulars | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 228 | 63 | 166 | 175 | 242 | 311 | 645 | 612 | 624 | 714 |
| Investing | -241 | -69 | -249 | -87 | -239 | -421 | -342 | -441 | -721 | -1,089 |
| Financing | -7 | 9 | 97 | -1 | -81 | 160 | 346 | -514 | -97 | 272 |
| Net Cash Flow | -20 | 3 | 14 | 87 | -78 | 50 | 648 | -343 | -194 | -103 |
| Free Cash Flow | 71 | -81 | -133 | -13 | 100 | 38 | 409 | 335 | 110 | -123 |
| CFO/OP | 108 | 93 | 135 | 121 | 131 | 89 | 118 | 98 | 89 | 90 |
Ratios
| Particulars | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 20 | 41 | 41 | 36 | 34 | 30 | 26 | 24 | 29 | 34 |
| Inventory Days | 28 | 26 | 26 | 43 | 42 | 36 | 35 | 32 | 28 | 29 |
| Days Payable | 92 | 124 | 142 | 147 | 138 | 90 | 114 | 90 | 81 | 89 |
| Cash Conversion Cycle | -45 | -56 | -75 | -67 | -62 | -24 | -52 | -34 | -24 | -26 |
| Working Capital Days | -23 | -33 | -18 | -31 | -48 | -20 | -37 | -32 | -21 | -7 |
| ROCE % | — | — | 6% | 6% | 5% | 15% | 17% | 20% | 20% | 17% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Global Health insights
62 extracted metrics + investor summaries across FY16–FY27.
Documents
Frequently Asked Questions about Global Health
What does Global Health Ltd do?
Where is Global Health Ltd (MEDANTA) listed?
Which sector does Global Health Ltd belong to?
What is the market capitalisation of Global Health Ltd?
What is the PE ratio of Global Health Ltd?
What is the 52-week high and low of Global Health Ltd?
Does Global Health Ltd pay dividends?
What is the Return on Equity (ROE) of Global Health Ltd?
Company Information
Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MEDANTA.md for Global Health Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.